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In the FANTOM5 project, transcription initiation events across the human and mouse genomes were
mapped at a single base-pair resolution and their frequencies were monitored by CAGE (Cap Analysis of
Gene Expression) coupled with single-molecule sequencing. Approximately three thousands of samples,
consisting of a variety of primary cells, tissues, cell lines, and time series samples during cell activation and
development, were subjected to a uniform pipeline of CAGE data production. The analysis pipeline started
by measuring RNA extracts to assess their quality, and continued to CAGE library production by using a
robotic or a manual workﬂow, single molecule sequencing, and computational processing to generate
frequencies of transcription initiation. Resulting data represents the consequence of transcriptional
regulation in each analyzed state of mammalian cells. Non-overlapping peaks over the CAGE proﬁles,
approximately 200,000 and 150,000 peaks for the human and mouse genomes, were identiﬁed and
annotated to provide precise location of known promoters as well as novel ones, and to quantify their
activities.
Design Type(s)
organism part comparison design • species comparison design • cell type
comparison design • organism development design
Measurement Type(s) DNA-templated transcription, initiation
Technology Type(s) cap analysis of gene expression
Factor Type(s) Species • Organism Part • life cycle stage • cell type
Sample Characteristic(s)
Mus musculus • cerebellum • visual cortex • ileum • Peyer's patch •
stomach • axillary lymph node • aorta • substantia nigra • hippocampal
formation • brain • heart • liver • meningeal cluster • bone marrow •
spinal cord • raphe nuclei • corpus striatum • cortex • peripheral nervous
system • kidney • neural system • hemolymphoid system • blood •
spleen • mesoderm • hematopoietic system • ventral wall of dorsal aorta
• placenta • ganglion • spiral organ of cochlea • small intestine •
intestine • adrenal gland • eyeball of camera-type eye • pituitary gland •
thymus • lung • female gonad • testis • bone tissue • diencephalon •
muscle organ • medulla oblongata • forelimb • pancreas • gonad •
corpora quadrigemina • skin of body • tongue • colon • caecum •
vesicular gland • epididymis • amnion • mammary gland • uterus •
submandibular gland • prostate gland • intestinal mucosa • urinary
bladder • vagina • oviduct • Homo sapiens
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Background & Summary
Since the completion of the human genome sequencing, role of individual bases has been a central
question. An international collaborative effort, FANTOM (Functional ANnoTation Of Mammalian
Genome)1, delineated a complex landscape of transcribed RNAs (transcriptome) and their regulations.
The initial key technology driving the project was to make full-length cDNA clones, representing
complete primary structure of transcribed RNA molecules. Sequencing of the full-length cDNA clones
uncovered unexpected number of long non-coding RNAs as well as protein coding genes2–6. The
CAGE (Cap Analysis Gene Expression)7,8 protocol, combination with high-throughput sequencing,
was developed to monitor frequencies of transcription initiation by determining 5′-end of capped
RNAs. The technology was devised to uncover complexity of the transcriptome4–6 and elucidate
transcriptional regulatory networks by focusing on promoter elements9–12. By taking advantage of
single molecule sequencer, HeliScopeCAGE was recently developed to provide more sensitive and
accurate monitoring of transcription initiation activities7,8.
In the ﬁfth round of the FANTOM projects, FANTOM5, the challenge was to capture the
transcriptome of many varieties of cell states as possible, to understand the implication of each genomic
bases in different contexts. In the ﬁrst phase of the FANTOM5 project, we targeted cells in steady state,
called ‘snapshot’ samples13. Our central focus was on human primary cells, while cell lines, tissues and
mouse samples were chosen to cover cells inaccessible as isolated human primary samples. The resulting
data provided an atlas of promoter and enhancer activities in wide range of cell states14, which is a
baseline of understanding complex transcriptional regulation. In the second phase, we focused on
transitions of cell states by monitoring ‘time course’ samples, such as activations, differentiations,
and developments at sequential time points15. The monitored activities of promoters and
enhancers demonstrated that enhancer activities is the earliest event during dynamic changes of
transcriptome. These data sets are being utilized in many other studies inside and outside of the
FANTOM5 consortium.
The data production scheme was implemented based on the FANTOM5 collaboration. Sample
collection was performed at individual institutes, since speciﬁc types of samples require dedicated
systems with special expertise or settings, as well as through purchase from commercial sources. RNA
quality was ﬁrstly examined at the place where the samples were obtained (the ﬁrst RNA quality check).
The CAGE assay pipeline established in RIKEN GeNAS (Genome Network Analysis Support Facility)
employed two workﬂows of HeliScopeCAGE, a manual workﬂow for samples with small amount of
total RNAs8 and a robotic workﬂow for samples with standard requirements7. The assay pipeline
started with checking RNA quality (the second RNA quality check), which provides a uniform quality
assessment of the proﬁled RNA extracts. The resulting CAGE libraries were sequenced by HeliScope in
RIKEN and also in Helicos Biosciences, and the obtained data were processed by the MOIRAI system16.
Quality of the resulting CAGE proﬁles was checked with several statistics as well as manual inspection
by using the ZENBU browser17. Finally CAGE proﬁles were shared among the consortium for further
analysis.
In the course of the two phases focused on ‘snapshot’ and ‘time course’ samples, we proﬁled 1,816
human and 1,016 mouse samples in total, and obtained approximately four millions of single-molecule
reads successfully aligned to the genome per sample on average. Based on frequencies of the observed 5′-
ends of individual capped RNA molecules at a single base-pair resolution, we identiﬁed 201,802 and
158,966 peaks for human and mouse respectively, where promoters are deﬁned as the sequence
immediately upstream of the peaks and frequencies of observed CAGE reads reﬂect activities of the
promoters. All data generated during the course of the project were deposited to a public repository (DDBJ
Read Archive, DRA) and/or provided at the FANTOM5 web resource (http://fantom.gsc.riken.jp/5/)18.
Here we describe the data with the processing details and quality metrics.
Sample Phase 1 Phase 2 Total
Human Mouse Human Mouse
Cell lines 259 1 9 0 269
Fractionations 12 0 9 0 21
Primary cells 537 109 24 31 701
Timecourse samples 35 19 748 572 1,374
Tissues 150 237 33 45 465
Quality control samples 0 1 0 1 2
Total 993 367 823 649 2,832
Table 1. Summary of FANTOM5 phase 1 and phase 2 samples.
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Methods
Sample collection
Sample collection was performed as described previously13,15. Brieﬂy, primary cells were purchased as
puriﬁed RNAs or frozen cells, or obtained as described previously19–24 through collaboration in the
consortium. Purchased cells were cultured according to the manufacturer’s instructions and miRNeasy kit
(QIAGEN) was used for RNA extraction. Human post mortem tissue RNAs were purchased or obtained
through the Dutch Brain bank. Tissues collected through the consortium were snap-frozen in liquid
nitrogen, transferred into Lysing Matrix D tubes (MP Biomedicals, Santa Ana, CA) containing chilled
Trizol (Gibco), homogenized by FastPrep Homogenizer (Thermo Savant), and centrifuged. miRNeasy kit
(QIAGEN) was used for RNA extraction from cultured cell lines as well as frozen cell line stocks.
For the purchased samples, lot or catalogue numbers were recorded where available. Of the collected
RNAs, those with more than 1 μg, were measured by Agilent BioAnalyzer (Agilent Technologies, Santa
Clara, CA) and Nanodrop spectrophotometer (Thermo Fisher Scientiﬁc, Wilmington, DE) to check RIN
(RNA integrity) score and the absorbance ratio of A260/A230 and A260/A280. The rest of the samples
were directly subjected to the CAGE library production to avoid wasting material. All 2,832 proﬁled
samples are summarized in Table 1.
Single molecule CAGE and data processing
HeliScopeCAGE libraries were prepared, sequenced, and processed as described previously13,15. Most of
the RNAs were subjected to the automated HeliScopeCAGE protocol7, except for RNAs with less than 1
μg that were subjected to the manual protocol optimized for low quantity RNAs8. The resulting libraries
were measured by OliGreen ﬂuorescence assay kit (Life Technologies), and sequenced by following the
manufacturer’s instructions (LB-016_01, LB-017_01, and LB-001_04 (ref. 13). RNAs extracted from
mouse whole body embryo E17.5 (called internal control) were systematically subjected to this workﬂow,
with one per a sequencing run.
The produced data were processed as previously described13,15. Brieﬂy, reads corresponding to
ribosomal RNA were removed by using the program rRNAdust (http://fantom.gsc.riken.jp/5/suppl/
rRNAdust/), remaining reads were aligned to the reference genome of human and mouse (hg19 or mm9)
by using Delve25, and alignments with a quality of less than 20 (o99% chance of true) or a sequence
identity of less than 85% were discarded. Frequencies of the CAGE read 5′ ends were counted to give a
unit of CAGE tag start site (CTSS), a single base-pair on the reference genome. The entire ﬂow of the data
is illustrated in Fig. 1, and the number of CAGE proﬁles (equivalent to CTSS ﬁles) is summarized in
Table 2.
Identiﬁcation of peaks and their annotations
Non-overlapping peaks based on the all CAGE proﬁles were identiﬁed by using DPI (decomposition-
based peak identiﬁcation, https://github.com/hkawaji/dpi1/) method and annotated as previously
described13,15. A ‘robust’ threshold, for which a peak must include a CTSS with more than 10 read counts
and 1 TPM (tags per million) at least one sample, was employed to deﬁne a stringent subset of the CAGE
peaks. The robust peaks were associated with known transcripts, such as RefSeq26, UCSC known gene27,
GENCODE28, Ensembl29, and mRNAs (full-length cDNA clones), based on their 5′-end proximity to the
peaks. Ofﬁcial gene symbols, Entrez Gene IDs, and protein (UniProt) IDs associated with the transcripts
were retrieved and assigned as part of annotation. In addition to these associations, human readable
names and descriptions were assigned to each of the CAGE peaks. Peaks were given a name in the form
pN@GENE, where GENE indicates gene symbol or transcript name and N indicates the rank in the
ranked list of promoter activities for that gene. For example, p1@SPI1 represent the peak with the highest
number of observation (that is, read counts) in all of the FANTOM5 CAGE proﬁles, among the peaks
associated with SPI1 gene.
Peak identiﬁcation with the same method and the same threshold was performed two times; the ﬁrst
was for ‘snapshot’ samples (phase 1), and the second was for the entire samples from both the ‘snapshot’
Sample Phase 1 Phase 2 Total
Human Mouse Human Mouse
Cell lines 261 1 10 0 272
Fractionations 12 0 9 0 21
Primary cells 538 110 26 50 724
Timecourse samples 35 20 750 578 1,383
Tissues 152 236 36 45 469
Quality control samples 0 28 0 122 150
Total 998 395 831 795 3,019
Table 2. Sequence ﬁles (CTSS ﬁles).
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and ‘time course’ studies (phase 2). We integrated these two peak sets into a hybrid set consisting of all
the phase 1 peaks over the robust threshold and a subset of phase 2 peaks that did not overlap with the
phase 1 peaks. Annotation of phase1 peaks was used in the hybrid set, called phase 1+2 peaks, which
provide a consistent reference in the deﬁnition of promoters.
Quantiﬁcation of promoter activities
All the obtained CAGE proﬁles were subjected to the peak identiﬁcation, even if they have some issues in
quality, since all of them still represent independent observations of RNA 5′-ends. However promoter
activities (that is, expression levels of CAGE peaks) were quantiﬁed only in the samples satisfying the
following criteria: RIN score greater than 6, more than 500,000 successfully aligned reads to the genome,
and more than 50% of the successful alignments are close to 5′-end of RefSeq gene model, for expression
analysis requiring reliable quantiﬁcation. After discarding a few CAGE proﬁles of low quality, read counts
for individual CTSSs belonging to the same peak were summed up, normalization (or scaling) factors
were calculated with RLE (Relative Log Expression)30 method by edgeR31, and tags per million (that is,
counts per million) was computed as expression levels.
The RLE normalization was ﬁrst performed within the phase 1 samples. The naïve application of this
to the entire data sets, consisting of phase 1 and phase 2 samples, might cause inconsistencies in
expression levels between the two normalizations. To avoid this, we took the geometric mean of CAGE
peak read counts across the phase 1 samples and used it as the reference expression for a normalization
factor calculation in the same manner as RLE method. This enabled us to keep the expression levels of
phase 1 as they were, and to adjust the expression levels of the phase 2 samples to be comparable15.
Code availability
All software used in this study are publicly available. rRNAdust, for removing ribosomal RNA, is available
at http://fantom.gsc.riken.jp/5/suppl/rRNAdust/. Mapping software Delve is available at http://fantom.
gsc.riken.jp/5/suppl/delve/. The program to perform DPI, decomposition-based peak identiﬁcation,
method is available at https://github.com/hkawaji/dpi1/.
Data Records
Data record 1: Metadata
Two types of metadata are available at ﬁgshare and LSDB Archive (Data Citation 1, 10). One is for the
samples, including their origins and extracted RNA. The other is for the CAGE assay, including the result
of RNA quality check, library production, and post-processing of the CAGE tag sequences. Both of them
are described in SDRF (Sample and Data Relationship Format)32. Sample metadata for human and mouse
are ‘HumanSamples2.0.sdrf.xlsx’ and ‘MouseSamples2.0.sdrf.xlsx’, respectively. The metadata for the
CAGE assay are available as ‘*sdrf.txt’.
Data record 2: CAGE proﬁles
All of the CAGE sequences, their alignment to the genomes, and CTSS frequencies are available at DDBJ
DRA (DDBJ Sequence Read Archive) (Data Citations 2–9). The accession number of each ﬁle is
summarized in ‘DRA*.txt’ at ﬁgshare (Data Citation 1).
Data record 3: CAGE peaks
Genomic coordinates, annotations and expressions of the CAGE peaks are available as ‘*phase1and2-
combined_coord.bed.gz’, ‘*phase1and2combined_ann.txt.gz’, and ‘*phase1and2combined_tpm.osc.txt.gz’
Figure 1. Data processing scheme. Data processing scheme from sample preparation to CAGE peak
expression and annotation. Sky blue and beige color indicate locations storing the data, the FANTOM5 data
archive (Data Citation 1, 10) and in DDBJ Sequence Read Archive (Data Citations 2–9) respectively.
www.nature.com/sdata/
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respectively at ﬁgshare (Data Citation 1). Genomic coordinates are formatted in BED format, and the
others are formatted in OSCtable (Order Switchable Column table). The detail of the OSCtable format is
available at https://sourceforge.net/projects/osctf/.
Technical Validation
RNA quality
Measured RNA qualities at the second check (that is, immediately before the CAGE library production)
are shown in Fig. 2a–c. RNA Integrity Number (RIN) score, measured using an Agilent Bioanalyzer, was
8.96 on average (standard deviation 1.19), absorbance ratio of 260/230 nm (A260/A230) and 260/280 nm
(A260/A280) were on average 2.01 (standard deviation 0.53) and 2.13 (standard deviation 0.14)
respectively. These ﬁgures indicate that the majority of the RNAs were processed in good quality.
Mapped reads
The number of CAGE reads successfully aligned with the genome and the ratio of CAGE reads hitting
conventional promoters are shown in Fig. 2d,e. The average number of mapped reads is 4,208,291 per
CAGE proﬁle. Of the 2,522 proﬁles, 98.3% (2,478) consists of at least 500,000 successfully aligned reads,
which was a criterion of proﬁles used for expression analysis13. The average ratio of promoter-hitting
reads is 76.5, and 98.6% of the all proﬁles (2,437/2,472) have more than 50% promoter-hitting rate, which
was another criterion of proﬁles used for expression analysis13.
Sample identity
Hierarchical clustering of the 126 mouse primary cells13 within the phase 1 was shown in Fig. 3, and the
same clustering of the 571 human primary cells13 was in Supplementary Fig. 1. The average linkage
method was applied to log-scale expression (TPM) proﬁles at promoter-level, and sample identities were
assessed by expression of marker genes and also by manual inspection of the hierarchical clustering. The
ﬁgures show that majority of biological replicates belonged to the same branch of the tree, that is, the
same cluster, except for samples with a low number of mapped read counts.
Figure 2. RNA and mapping quality control. Distribution of RIN score (a), A260/A230 (b), A260/A280 (c),
mapped reads (d), and promoter rate (e) for samples used for FANTOM5 expression analysis.
www.nature.com/sdata/
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Figure 3. Hierarchical clustering of primary cells. Hierarchical clustering of primary cell samples of mouse
based on logarithm of expression (TPM). Color shows anatomical categories of samples.
www.nature.com/sdata/
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Usage Notes
As well as providing access to individual data ﬁles, we also set up a series of interfaces as described in the
FANTOM web resource18,33. TET (Table Extraction Tool) provides an interface to obtain a subset of data
by specifying the desired columns and rows. The BioMart interface34, and FANTOM5 SSTAR (Semantic
catalog of Samples, Transcription initiation And Regulators) provides the metadata of the proﬁled
samples35. The CAGE proﬁle on the genomic axis is visible in ZENBU17 with its interactive interface and
also in the UCSC genome browser36 via track data hub37.
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